MAAT INDEX

CLAIM #18594 · CVS Health Corp (CVS) · 2025Q3 earnings call · Oct 29, 2025 · due Dec 31, 2026

We also expect a tailwind from our exit of the individual exchange business.

Brian O. Newman · CFO

CANNOT_DETERMINE
versus commitment · official band 5 percent
Committed
We also expect a tailwind from our exit of the individual exchange business.
Reported
This increase was primarily driven by our government business, partially offset by our exit from the Individual Exchange business in 2026.

How to check this claim

Look at: Health Care Benefits (Aetna) segment adjusted operating income margin improvement year-over-year for FY2026, specifically attributed to exit of individual exchange business

It came true if: FY2026 Health Care Benefits segment adjusted operating income margin higher than FY2025 reported margin

Where: Company Q4/FY2026 earnings release and 10-K segment disclosures, and management commentary at December 2025 Investor Day / FY2026 guidance

In context

ion to $8 billion. Additionally, we now expect our full year adjusted effective tax rate to be 25.3%, an improvement of 40 basis points. You can find additional details on the components of our 2025 guidance on our Investor Relations website. Before we open the call up to Q&A, I also want to provide an update on some of the key headwinds and tailwinds for 2026. Consistent with past practice, we expect to provide formal 2026 guidance at our Investor Day in December. Beginning with our Health Care Benefits business, we expect another year of meaningful margin improvement at Aetna. This includes another year of progress in our Medicare Advantage business, supported by our disciplined approach to plan design and footprint in individual as well as repricing opportunities in our group business. We also expect a tailwind from our exit of the individual exchange business. Although our conversations with our Medicaid state partners continue to progress and this business has performed in line with our expectations this year, we are taking a cautious outlook in light of the broader pressures across the industry. In our Health Services segment, we expect improvement in our Health Care Delivery business, primarily driven by Oak Street Health. In our Caremark business, we expect modestly lower growth as we continue our work to transition our contracts towards drug level pricing over the next few years. Altogether, we expect the segment to deliver low single-digit adjusted operating income growth next year. And in our Pharmacy & Consumer Wellness segment, we are encouraged by our strong performance this year and expect this momentum to continue into next year. Wh

Verify independently

SEC filings for CVS · Claim quote is verbatim from the 2025Q3 earnings call.